HIV mRNA vaccine strategies for efficient priming, diversity and durability of immune responses

Document text

Principal Investigator: PARHAM  RAMEZANI-RAD
Organization: LA JOLLA INSTITUTE FOR IMMUNOLOGY
Fiscal Year: 2024
Award: $892,826
Funding agency: National Institute of Allergy and Infectious Diseases

SUMMARY
Conventional vaccine strategies have not induced successful protection to diverse HIV strains. mRNA vaccine
platforms enable novel modalities of antigen delivery for innovative vaccine strategies. The use of mRNA
technology for HIV vaccines holds promise to conquer major barriers to induce protective responses via
broadly neutralizing antibodies (bnAbs). However, mRNA vaccines to express HIV antigens capable of
effectively conferring protective immunity have not been fully explored. Germinal center (GC) responses are
paramount for prophylactic vaccines as they provide a highly specialized environment to affinity mature
antibodies to difficult epitopes on HIV. We have demonstrated that efficient priming and longer duration of GC
responses are likely favorable for broader neutralizing responses against HIV (Nature 2022). mRNA vaccines
against SARS-CoV-2 have been shown to induce long-lasting GC responses after 2 doses, but the biology and
effective manipulation of this process remains elusive. Particularly, a big knowledge gap is how mRNA
vaccine-induced GCs differ from protein vaccines. A second knowledge gap is what mechanisms drive long-
lasting GCs? A third knowledge gap is what immunological signals regulate the output of durable immune
memory? HIV envelope (Env) trimer is the sole antigenic target for neutralizing antibodies. Many experimental
HIV vaccines use soluble forms of Env that expose the immunodominant base of the trimer eliciting non-
neutralizing antibodies. mRNA vaccines allow the realization of membrane-bound Env expression, which can
present antigen in a more native form avoiding exposure of the base. Membrane-bound Env trimers can also
be expressed on nanoparticles such as virus-like particles (VLPs) via mRNA delivery resembling higher density
expression on native virions. Given the potential of long-lasting GC responses and the new modes of antigen
delivery by membrane-bound Env or multimeric Env nanoparticles, we seek to investigate: Are HIV mRNA
vaccines capable of inducing long-lasting GC responses? How can HIV mRNA vaccines optimally prime long-
lasting GC responses? What sequential immunization strategies work best with HIV mRNA vaccines to induce
diverse and durable memory responses? Non-human primates (NHPs) are an invaluable model for studying
this biology and immunology, because of their relatedness to humans.

Terms: <2019-nCoV vaccine><AIDS Virus><AIDS prevention><Ab response><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affinity><Animals><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antigen Presentation><Antigenic Determinants><Antigens><Autologous><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Biology><COVID-19><COVID-19 vaccine><CV-19><Complex><Coronavirus Infectious Disease 2019><Dose><Environment><Epitopes><FNA><Fine Needle Aspirate><Fine needle aspiration biopsy><Fine-Needle Aspiration><Germinal Center><HIV><HIV Antigens><HIV Prevention><HIV envelope><HIV envelope protein><HIV vaccine><HIV-Associated Antigens><HIV/AIDS Vaccines><HIV/AIDS prevention><HTLV-III Antigens><HTLV-III-LAV Antigens><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Antigens><Immune memory><Immune response><Immune signaling><Immunity><Immunization><Immunize><Immunobiology><Immunochemical Immunologic><Immunologic><Immunologic Memory><Immunological><Immunological Memory><Immunological response><Immunologically><Immunologics><Immunology><Immunophysiology><Intramuscular><Kinetics><Knowledge><LAV Antigens><LAV-HTLV-III><Lymphadenopathy-Associated Antigens><Lymphadenopathy-Associated Virus><Membrane><Memory><Mice><Mice Mammals><Modality><Modern Man><Molecular Interaction><Murine><Mus><Nature><Output><Phase><Preventative vaccine><Preventive vaccine><Process><Prophylactic vaccine><Proteins><Regimen><Route><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Speed><Structure of germinal center of lymph node><Study models><Technology><Testing><Vaccines><Virion><Virus Particle><Virus-HIV><Virus-like particle><Work><anamnestic reaction><antibody biosynthesis><base><bases><clinical development><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus infectious disease-19><density><design><designing><draining lymph node><host response><human immunodeficiency virus vaccine><immune system response><immunization strategy><immunogen><immunogenic><immunoglobulin biosynthesis><immunoresponse><improved><innovate><innovation><innovative><membrane structure><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano-sized particle><nanoparticle><nanosized particle><neglect><neutralizing antibody><non-human primate><nonhuman primate><novel><regional lymph node><response><secondary immune response><subcutaneous><subdermal><translation strategy><translational approach><translational strategy><vaccination strategy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine platform><vaccine strategy><vaccines preventing COVID><vaccines to prevent COVID><virus envelope><virus-like nanoparticles><viruslike particle>